BACKGROUND/AIMS: Soluble CD163 (sCD163) is a scavenger receptor shed in serum during inflammatory activation of macrophages. We investigated if sCD163 was increased and predicted outcome in acute liver failure (ALF). METHODS: Samples from 100 consecutive patients enrolled in the U.S. ALF Study Group for whom sera were available were collected on days 1 and 3, and clinical data were obtained prospectively. sCD163 levels were determined by ELISA. RESULTS: The median level of sCD163 was significantly increased in ALF (21.1mg/l (range 3.6-74.9)) as compared to healthy controls (2.3mg/l (0.65-5.6), p<0.0001) and patients with stable liver cirrhosis (9.8mg/l (3.6-16.9), p=0.0002). sCD163 on day 1 correlated significantly with ALT, AST, bilirubin, and creatinine. sCD163 concentrations on day 3 were elevated in patients with fatal outcome of disease compared to spontaneous survivors, 29.0mg/l (7.2-54.0) vs. 14.6mg/l (3.5-67.2), respectively (p=0.0025). Patients that were transplanted had intermediate levels. Sensitivity and specificity at a cut-off level of 26mg/l was 62% and 81%, respectively. CONCLUSIONS: Activated macrophages are involved in ALF resulting in a 10-fold increase in sCD163. A high level (>26mg/l) of sCD163 was significantly correlated with fatal outcome and might be used with other parameters to determine prognosis.
BACKGROUND/AIMS: Soluble CD163 (sCD163) is a scavenger receptor shed in serum during inflammatory activation of macrophages. We investigated if sCD163 was increased and predicted outcome in acute liver failure (ALF). METHODS: Samples from 100 consecutive patients enrolled in the U.S. ALF Study Group for whom sera were available were collected on days 1 and 3, and clinical data were obtained prospectively. sCD163 levels were determined by ELISA. RESULTS: The median level of sCD163 was significantly increased in ALF (21.1mg/l (range 3.6-74.9)) as compared to healthy controls (2.3mg/l (0.65-5.6), p<0.0001) and patients with stable liver cirrhosis (9.8mg/l (3.6-16.9), p=0.0002). sCD163 on day 1 correlated significantly with ALT, AST, bilirubin, and creatinine. sCD163 concentrations on day 3 were elevated in patients with fatal outcome of disease compared to spontaneous survivors, 29.0mg/l (7.2-54.0) vs. 14.6mg/l (3.5-67.2), respectively (p=0.0025). Patients that were transplanted had intermediate levels. Sensitivity and specificity at a cut-off level of 26mg/l was 62% and 81%, respectively. CONCLUSIONS: Activated macrophages are involved in ALF resulting in a 10-fold increase in sCD163. A high level (>26mg/l) of sCD163 was significantly correlated with fatal outcome and might be used with other parameters to determine prognosis.
Authors: Charalambos Gustav Antoniades; Philip A Berry; Edward T Davies; Munther Hussain; William Bernal; Diego Vergani; Julia Wendon Journal: Hepatology Date: 2006-07 Impact factor: 17.425
Authors: Lehn K Weaver; Katharine A Hintz-Goldstein; Patricia A Pioli; Kathleen Wardwell; Nilofer Qureshi; Stefanie N Vogel; Paul M Guyre Journal: J Leukoc Biol Date: 2006-07 Impact factor: 4.962
Authors: T H Sulahian; P Högger; A E Wahner; K Wardwell; N J Goulding; C Sorg; A Droste; M Stehling; P K Wallace; P M Morganelli; P M Guyre Journal: Cytokine Date: 2000-09 Impact factor: 3.861
Authors: Dominik J Schaer; Christian A Schaer; Gabriele Schoedon; Alexander Imhof; Michael O Kurrer Journal: Eur J Haematol Date: 2006-11 Impact factor: 2.997
Authors: Lucia A Possamai; Charalambos Gustav Antoniades; Quentin M Anstee; Alberto Quaglia; Diego Vergani; Mark Thursz; Julia Wendon Journal: World J Gastroenterol Date: 2010-04-21 Impact factor: 5.742
Authors: E S Andersen; S Rødgaard-Hansen; B Moessner; P B Christensen; H J Møller; Nina Weis Journal: Eur J Clin Microbiol Infect Dis Date: 2013-08-10 Impact factor: 3.267